icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
AMaRC 16-02 - RECRUITMENT CLOSED

STUDY TITLE

A prospective, multi-centre, single arm, phase 2 assessment of the efficacy and safety of the combination of ixazomib, thalidomide and dexamethasone (ITD) for relapsed and/or refractory multiple myeloma after 1 to 3 prior lines of therapy.

 

STUDY DESIGN

Multicentre, open label, prospective, single arm study

 

CORRELATIVE STUDIES

Blood and bone marrow samples are collected for assessment of minimal residual disease (MRd) and for purification and storage for potential future exploratory biomarker studies

 

TRIAL PRINCIPAL INVESTIGATOR

Professor Andrew Spencer

 

TIME FRAME

2016 – 2018

 

PARTICIPANTS

45 patients with relapsed refractory multiple myeloma (RR MM) who have received 1-3 prior lines of therapy

 

CURRENT ENROLMENT

40

 

STATUS

Closed to recruitment 

 

SITE LOCATIONS